OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

GALAPAGOS N.V./  BE0003818359  /

München
9/26/2024  8:02:01 AM Chg. 0.000 Volume Bid9:59:57 PM Ask9:59:57 PM Market Capitalization Dividend Y. P/E Ratio
25.760EUR 0.00% 0
Turnover: 0.000		 -Bid Size: - -Ask Size: - 1.72 bill.EUR - 8.14
Newsfile Corp 9/6 Metropolitan Touring Achieves Sustainability Benchmark with Carbon-Neutral Commitment
GlobeNewswire 8/27 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
GlobeNewswire 8/27 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
GlobeNewswire 8/23 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire 8/22 Inspirato Introduces “Inspirato Invited”
GlobeNewswire 8/20 Galapagos receives transparency notification from FMR LLC
GlobeNewswire 8/1 Galapagos reports half-year 2024 financial results and provides second quarter business update
GlobeNewswire 6/14 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire 5/30 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire 5/16 Galapagos creates new subscription right plans
GlobeNewswire 5/15 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire 5/2 Galapagos reports first quarter 2024 financial results  
GlobeNewswire 4/30 Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and E...
GlobeNewswire 4/4 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire 3/28 Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
GlobeNewswire 3/26 Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
GlobeNewswire 2/22 Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Cl...
GlobeNewswire 2/22 Galapagos announces full year 2023 results and outlook for 2024
GlobeNewswire 2/15 Galapagos presents at EBMT-EHA annual meeting 2024
GlobeNewswire 2/5 NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
GlobeNewswire 1/31 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
GlobeNewswire 1/4 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire 1/3 Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule dru...
GlobeNewswire 1/2 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
GlobeNewswire 12/22/2023 Oceana Finds China’s Fishing Fleet Swarms Galápagos, then Disappears from Sight